In obese male mice and non-human primates, blocking two specific proteins (GDF8 and activin A) while using a GLP-1 receptor agonist helps maintain or increase muscle mass and enhances fat loss, leading to better body composition and improved metabolic indicators like lower liver fat and healthier blood lipids.

14

Pro

0

Against

Evidence from Studies

Supporting (1)

14

Community contributions welcome

14

GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates

Randomized Controlled Trial

Animal

2025 May 13

This study found that when obese mice and monkeys were given a drug to reduce appetite (like those used in humans) plus another treatment that blocks two specific muscle-wasting signals, they kept more muscle and lost more fat — exactly what the claim says. It’s like stopping your body from breaking down muscle while it’s trying to lose weight.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates

Score: 14

DOI: 10.1038/s41467-025-59485-9

Similar Assertions

In obese male primates, combining a treatment that blocks two specific proteins (GDF8 and activin A) with GLP-1 therapy leads to larger improvements in blood sugar control and cholesterol levels than GLP-1 therapy by itself.

14

0

76%

In obese male mice, combining semaglutide with a treatment that blocks GDF8 and activin A leads to about twice as much fat loss over four weeks compared to semaglutide alone, even when total weight loss is the same, indicating that preserving muscle may help the body remove more fat.

14

0

75%

In obese male primates, combining a drug that blocks two specific muscle-regulating proteins with semaglutide leads to greater increases in muscle mass and more fat loss than semaglutide alone, along with improved blood sugar and cholesterol levels after 20 weeks of treatment.

14

0

73%

Medications that mimic a gut hormone called GLP-1 can make people feel less hungry, eat less food, and lose body fat over time.

0

70%